minktherapeutics.com (INKT): Utang marang Ekuitas

Logo korporat perusahaan MiNK Therapeutics, Inc (INKT)

The financial quote visualization for the total debt-to-equity ratio for MiNK Therapeutics, Inc. (INKT) is 0.00. MiNK Therapeutics, Inc. (INKT) develops universal iNKT drugs capable of destroying tumors without the risk of rejection. Development is conducted through partnerships with oncology centers, which accelerates the launch of clinical trials. The business's financial success is tied to the results of molecule testing within the medical cycle, remaining independent of the external economy.

INKT: Rasio Total Utang marang Ekuitas MiNK Therapeutics 04.07.2022 - 01.11.2026

Rincian metrik komprehensif lan analitis MiNK Therapeutics, Inc (INKT)

- rega lan prakiraan konsensus rega:
Bagan rega MiNK Therapeutics|INKT - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar MiNK Therapeutics|INKT - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham MiNK Therapeutics|INKT - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku minktherapeutics.com|INKT - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas MiNK Therapeutics, Inc.|INKT - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas MiNK Therapeutics, Inc.|INKT - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku MiNK Therapeutics|INKT - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan MiNK Therapeutics|Indikator likuiditas cepet minktherapeutics.com
- informasi bathi lan kelipatan valuasi:
INKT - Bathi pungkasan
Analisis fundamental perusahaan:MiNK Therapeutics, INKT
Barang utama MiNK Therapeutics, Inc.

Investors must balance the profit potential of biotech assets against the risks of excessive financial leverage. By analyzing the total debt-to-equity ratio, one can assess the business's reliance on borrowed funds, which is critical for MiNK Therapeutics, Inc. (INKT) as it prepares for clinical releases of iNKT therapy, a period when financial stability determines the company's ability to complete costly research without the risk of bankruptcy.

Pesaing MiNK Therapeutics, Inc. (INKT)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Arcus Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal ZYME (Zymeworks Inc.)|TNGX - Rasio Total Utang marang Ekuitas|IOVA - Utang marang Ekuitas|Utang marang Modal Immatics NV|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas Replimune Group, Inc.|Utang marang Modal lyell.com LYEL|Total Utang marang Modal IPHA|pyxisoncology.com (PYXS) - Rasio Utang marang Modal|Compugen - Rasio Total Utang marang Ekuitas|IO Biotech Inc. (IOBT) - Utang marang Modal|STRO: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi HOWL (Werewolf Therapeutics)|IMMX: Total Utang marang Modal|ALXO - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cue Biopharma, Inc.|Rasio Total Utang marang Ekuitas PDS Biotechnology Corp (PDSB)|Utang marang Ekuitas Sonnet BioTherapeutics (SONN)|Rasio Total Utang marang Ekuitas MAIABiotech.com MAIA|Liminatus Pharma LLC - Rasio Total Utang marang Ekuitas|Total Utang marang Modal LAVA Therapeutics NV LVTX|NXTC - Utang marang Ekuitas|LPTX (Leap Therapeutics, Inc.) - Rasio Utang marang Ekuitas|intensitytherapeutics.com (INTS) - Utang marang Ekuitas|Utang marang Modal Sensei Biotherapeutics, Inc. (SNSE)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal